“Bimekizumab Efficacy and Safety Through 3 Years in Patients With Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT”. 2026. SKIN The Journal of Cutaneous Medicine 10 (2): s762. https://doi.org/10.25251/g776yf41.